胆固醇流出调节蛋白与胆固醇逆向转运

高密度脂蛋白（ＨＤＬ）能从外周细胞摄取我余胆固醇并运输至肝脏排出,防止其在血管壁沉积。外周细胞内胆固醇流向ＨＤＬ的机制一直是人们积极探索但尚未弄清的问题。新近发表在《Ｎａｔｕｒｅ Ｇｅｎｅｔｉｃｓ》上的三篇论文在这个环节上取得了重大突破,他们通过对Ｔａｎｇｉｅｒ病的研究,发现由ＡＴＰ－ｂｉｎｄｉｎｇ－ｃａｓｓｅｔｔｅ ｔｒａｎｓｐｏｒｔｅｒ １基因编码的胆固醇流出调节蛋白（ｃｈｏｌｅｓｔｅｒｏｌ－     

急性期应答与胆固醇逆向转运

胆固醇逆向转运(reverse cholesterol transport,RCT)是促进外周胆固醇从细胞内流出,然后转运到肝脏进行代谢的过程,是机体抗动脉粥样硬化相关疾病的重要机制。研究表明,感染、炎症及创伤等诱导的急性期应答(acute phase response,APR)影响高密度脂蛋白的结构和功能,抑制细胞内胆固醇流出、血浆胆固醇转运及肝脏胆固醇代谢和排泌等环节,因此抑制体内RCT。APR短期抑制RCT有利于机体抗感染和组织损伤,然而,APR对RCT的进一步抑制将促进外周组织胆固醇蓄积及代谢紊乱,可能是多种感染免疫性疾病、代谢性疾病与动脉粥样硬化呈正相关的关键因素。本文就APR调节机体RCT的最新研究进展作一综述。     

高密度脂蛋白受体在胆固醇逆行转运中的作用

本文综述了近两三年来HDL受体及其在胆固醇逆行转运过程中作用的研究进展,着重讨论了肝外细胞及肝组织细胞HΓL受体介导胆固醇转移的机理。     

植物乳杆菌ZDY04促进胆固醇逆向转运减轻TMAO诱导的ApoE-/-小鼠动脉粥样硬化

目的 探讨植物乳杆菌ZDY04能否改善氧化三甲胺(TMAO)诱导的小鼠动脉粥样硬化及其机制.方法 6～8周龄雌性载脂蛋白E基因敲除(apolipoprotein E-deficient mice,ApoE-/-)小鼠被随机分成3组:正常饮食组(Chow组)、胆碱+溶剂组(Choline+PBS组)和Choline+ZD...     

巨噬细胞胆固醇转运相关蛋白研究进展

动脉粥样斑块中泡沫细胞的形成与巨噬细胞胆固醇的转运密切相关,巨噬细胞胆固醇转运是胆固醇逆转运中的一个重要过程,它可清除外周组织过多的胆固醇,对维持细胞内胆固醇稳定、延缓动脉粥样硬化的发生发展有着重要意义.这个过程涉及到许多转运相关蛋白的作用,如三磷酸腺苷结合盒转运体A1/G1、载脂蛋白A-Ⅰ、胆固醇脂转运蛋白、卵磷脂胆固醇酰基转移酶等.本文就巨噬细胞胆固醇转运过程中相关蛋白的作用做一综述,以期为动脉粥样硬化相关疾病的防治研究提供新的思路.     

细胞内胆固醇的转运和区域化

细胞内胆固醇的转运和区域化黎玉（江西医学院化学教研室,南昌３３０００６）关键词细胞胆固醇转运区域化胆固醇是生物膜的重要成分,也是合成甾体激素、胆汁酸和脂蛋白的前体。近来,对胆固醇的研究取得了一些进展［１］。本文将摘要介绍细胞胆固醇的分布、膜胆固醇区域...     

内质网区蓖麻毒素的逆向转运

蓖麻毒素是植物来源的核糖体失活蛋白。蓖麻毒素必须通过细胞的内膜系统到达内质网,然后转位至胞质,才能作用于胞质内的核糖体。在内质网中毒素的两条链分离,具有催化活性的A链被内质网上的蛋白质识别,并被转位到胞质内催化核糖体失活。现对内质网在参与蓖麻毒素胞内转运过程中的作用进行综述。     

膜转运蛋白ABCA1的结构与功能

膜转运蛋白ABCA1可以将包括胆固醇、磷脂在内的多种物质由细胞内转运至胞外,发挥抗动脉硬化的功能,它的突变可以导致严重的HDL缺乏综合征。该就ABCA1的结构与功能关系,作用机制,调控等方面做一简要介绍。     

视黄醇转运的分子机制

本文从视黄醇（维生素Ａ）的载体蛋白（ＲＢＰ０在内醇转运中的作用和结构特点,结合内醇的ＲＢＰ与前白蛋白（ＴＴＰ）的作用,视黄醇的转运及膜受体的性质等方面介绍视黄醇转运到靶细胞的分子机制。     

蓖麻毒素在细胞内逆向转运途径的研究进展

蓖麻毒素(Ricin)是一种毒蛋白,能抑制蛋白质合成.近年来被用来合成肿瘤导向药物一免疫毒素,在临床应用中仍具有一定的副作用.研究Ricin在细胞内的逆向转运途径有助于其在临床应用中更加完善.本文就Ricin在细胞内的逆向转运途径作一综述.     

Is reverse cholesterol transport regulated by active cholesterol?

This review considers the hypothesis that a small portion of plasma membrane cholesterol regulates reverse cholesterol transport in coordination with overall cellular homeostasis. It appears that almost all of the plasma membrane cholesterol is held in stoichiometric complexes with bilayer phospholipids. The minor fraction of cholesterol that exceeds the complexation capacity of the phospholipids is called active cholesterol. It has an elevated chemical activity and circulates among the organelles. It also moves down its chemical activity gradient to plasma HDL, facilitated by the activity of ABCA1, ABCG1, and SR-BI. ABCA1 initiates this process by perturbing the organization of the plasma membrane bilayer, thereby priming its phospholipids for translocation to apoA-I to form nascent HDL. The active excess sterol and that activated by ABCA1 itself follow the phospholipids to the nascent HDL. ABCG1 similarly rearranges the bilayer and sends additional active cholesterol to nascent HDL, while SR-BI simply facilitates the equilibration of the active sterol between plasma membranes and plasma proteins. Active cholesterol also flows downhill to cytoplasmic membranes where it serves both as a feedback signal to homeostatic ER proteins and as the substrate for the synthesis of mitochondrial 27-hydroxycholesterol (27HC). 27HC binds the LXR and promotes the expression of the aforementioned transport proteins. 27HC-LXR also activates ABCA1 by competitively displacing its inhibitor, unliganded LXR. 4 Considerable indirect evidence suggests that active cholesterol serves as both a substrate and a feedback signal for reverse cholesterol transport. Direct tests of this novel hypothesis are proposed.     

Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice

Cholesterol acquired by extrahepatic tissues (from de novo synthesis or lipoproteins) is returned to the liver for excretion in a process called reverse cholesterol transport (RCT). We undertook studies to determine if RCT could be enhanced by up-regulating individual steps in the RCT pathway. Overexpression of 7alpha-hydroxylase, Scavenger receptor B1, lecithin:cholesterol acyltransferase (LCAT), or apoA-I in the liver did not stimulate cholesterol efflux from any extrahepatic tissue. In contrast, infusion of apoA-I.phospholipid complexes (rHDL) that resemble nascent HDL markedly stimulated cholesterol efflux from tissues into plasma. Cholesterol effluxed to rHDL was initially unesterified but by 24 h this cholesterol was largely esterified and had shifted to normal HDL (in mice lacking cholesteryl ester transfer protein) or to apoB containing lipoproteins (in cholesteryl ester transfer protein transgenic mice). Most of the cholesterol effluxed into plasma in response to rHDL came from the liver. However, an even greater proportion of effluxed cholesterol was cleared by the liver resulting in a transient increase in liver cholesterol concentrations. Fecal sterol excretion was not increased by rHDL. Thus, although rHDL stimulated cholesterol efflux from most tissues and increased net cholesterol movement from extrahepatic tissues to the liver, cholesterol flux through the entire RCT pathway was not increased.     

Molecular mechanism of reverse cholesterol transport: reaction of pre-beta-migrating high-density lipoprotein with plasma lecithin/cholesterol acyltransferase

A 70-75 kDa high-density lipoprotein (HDL) particle with pre-beta-electrophoretic migration (pre-beta(1)-HDL) has been identified in several studies as an early acceptor of cell-derived cholesterol. However, the further metabolism of this complex has not been determined. Here we sought to identify the mechanism by which cell-derived cholesterol was esterified and converted to mature HDL as part of reverse cholesterol transport (RCT). Human plasma selectively immunodepleted of pre-beta(1)-HDL was used to study factors regulating pre-beta(1)-HDL production. A major role for phospholipid transfer protein (PLTP) in the recycling of pre-beta(1)-HDL was identified. Cholesterol binding, esterification by lecithin/cholesterol acyltransferase (LCAT) and transfer by cholesteryl ester transfer protein (CETP) were measured using (3)H-cholesterol-labeled cell monolayers. LCAT bound to (3)H-free cholesterol (FC)-labeled pre-beta(1)-HDL generated cholesteryl esters at a rate much greater than the rest of HDL. The cholesteryl ester produced in pre-beta(1)-HDL in turn became the preferred substrate of CETP. Selective LCAT-mediated reactivity with pre-beta(1)-HDL represents a novel mechanism increasing the efficiency of RCT.     

Zymosan-mediated inflammation impairs in vivo reverse cholesterol transport

Inflammation has been proposed to impair HDL function and reverse cholesterol transport (RCT). We investigated the effects of inflammation mediated by zymosan, a yeast glucan, on multiple steps along the RCT pathway in vivo and ex vivo. Acute inflammation with 70 mg/kg zymosan impaired RCT to plasma, liver, and feces similarly by 17-22% (P < 0.05), with no additional block at the liver. Hepatic gene expression further demonstrated no change in ABCG5, ABCB4, and ABCB11 expression but a decline in ABCG8 mRNA (32% P < 0.05). Plasma from zymosan-treated mice had a 21% decrease in cholesterol acceptor ability (P < 0.01) and a 35% decrease in ABCA1-specific efflux capacity (P < 0.01) in vitro. Zymosan treatment also decreased HDL levels and led to HDL remodeling with increased incorporation of serum amyloid A. In addition, cholesterol efflux from cultured macrophages declined with zymosan treatment in a dose dependent manner. Taken together, our results suggest that zymosan impairs in vivo RCT primarily by decreasing macrophage-derived cholesterol entering the plasma, with minimal additional blocks downstream. Our study supports the notion that RCT impairment is one of the mechanisms for the increased atherosclerotic burden observed in inflammatory conditions.     

HDL and reverse cholesterol transport. Role of cholesterol ester transfer protein]

As most of peripheral cells are not able to catabolize cholesterol, the transport of cholesterol excess from peripheral tissues back to the liver, namely "reverse cholesterol transport", is the only way by which cholesterol homeostasis is maintained in vivo. Reverse cholesterol transport pathway can be divided in three major steps: 1) uptake of cellular cholesterol by the high density lipoproteins (HDL), 2) esterification of HDL cholesterol by the lecithin: cholesterol acyltransferase and 3) captation of HDL cholesteryl esters by the liver where cholesterol can be metabolized and excreted in the bile. In several species, including man, cholesteryl esters in HDL can also follow an alternative pathway which consists in their transfer from HDL to very low density (VLDL) and low density (LDL) lipoproteins. The transfer of cholesteryl esters to LDL, catalyzed by the Cholesteryl Ester Transfer Protein (CETP), might affect either favorably or unfavorably the reverse cholesterol transport pathway, depending on whether LDL are finally taken up by the liver or by peripheral tissues, respectively. In order to understand precisely the implication of CETP in reverse cholesterol transport, it is essential to determine its role in HDL metabolism, to know the potential regulation of its activity and to identify the mechanism by which it interacts with lipoprotein substrates. Results from recent studies have demonstrated that CETP can promote the size redistribution of HDL particles. This may be an important process in the reverse cholesterol transport pathway as HDL particles with various sizes have been shown to differ in their ability to promote cholesterol efflux from peripheral cells and to interact with lecithin: cholesterol acyltransferase.(ABSTRACT TRUNCATED AT 250 WORDS)     

Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters

Cholesteryl ester transfer protein (CETP) transfers cholesteryl ester (CE) and triglyceride between HDL and apoB-containing lipoproteins. Anacetrapib (ANA), a reversible inhibitor of CETP, raises HDL cholesterol (HDL-C) and lowers LDL cholesterol in dyslipidemic patients; however, the effects of ANA on cholesterol/lipoprotein metabolism in a dyslipidemic hamster model have not been demonstrated. To test whether ANA (60 mg/kg/day, 2 weeks) promoted reverse cholesterol transport (RCT), 3H-cholesterol-loaded macrophages were injected and (3)H-tracer levels were measured in HDL, liver, and feces. Compared to controls, ANA inhibited CETP (94%) and increased HDL-C (47%). 3H-tracer in HDL increased by 69% in hamsters treated with ANA, suggesting increased cholesterol efflux from macrophages to HDL. 3H-tracer in fecal cholesterol and bile acids increased by 90% and 57%, respectively, indicating increased macrophage-to-feces RCT. Mass spectrometry analysis of HDL from ANA-treated hamsters revealed an increase in free unlabeled cholesterol and CE. Furthermore, bulk cholesterol and cholic acid were increased in feces from ANA-treated hamsters. Using two independent approaches to assess cholesterol metabolism, the current study demonstrates that CETP inhibition with ANA promotes macrophage-to-feces RCT and results in increased fecal cholesterol/bile acid excretion, further supporting its development as a novel lipid therapy for the treatment of dyslipidemia and atherosclerotic vascular disease.